Henan Lingrui Pharmaceutical Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Wei Xiong
Algemeen directeur
CN¥1.8m
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | 1.5yrs |
Eigendom CEO | 0.6% |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Recent updates
An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued
Oct 28Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement
Oct 13If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity
Aug 07A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)
Jul 03Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 07Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point
May 02Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 04Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?
Feb 29CEO
Wei Xiong (39 yo)
1.5yrs
Tenure
CN¥1,804,900
Compensatie
Mr. Wei Xiong serves as General Manager and Chairman at Henan Lingrui Pharmaceutical Co. Ltd. since May 18, 2023 and served as its Managing Director.